SCHEDULE: Cormorant Asset Management and Bihua Chen Disclose 6.46% Stake in Biomea Fusion Post Public Offering

Cormorant Asset Management, LP and its managing member Bihua Chen have updated their beneficial ownership in Biomea Fusion, Inc. to an aggregate of 6.46% following the company's recent public offering.

Summary

• Cormorant Asset Management, LP and its affiliated entities, along with Bihua Chen, have filed an Amendment No. 2 to their Schedule 13D regarding their beneficial ownership of Biomea Fusion, Inc. Common Stock.
• The aggregate beneficial ownership reported for Bihua Chen is 3,681,664 shares, representing 6.46% of the Issuer's Common Stock.
• Cormorant Asset Management, LP beneficially owns 3,570,872 shares, equating to 6.26% of the Common Stock.
• Cormorant Global Healthcare Master Fund, LP and Cormorant Global Healthcare GP, LLC each report shared voting and dispositive power over 1,795,928 shares, representing 3.15% of the class.
• Cormorant Private Healthcare Fund III LP and Cormorant Private Healthcare GP III, LLC each report shared voting and dispositive power over 1,717,232 shares, representing 3.01% of the class.
• The percentages of ownership are calculated based on 57,022,250 shares of Common Stock outstanding following the closing of a public offering on June 20, 2025.
• Bihua Chen's reported shares include 110,792 shares she has the right to receive within 60 days upon the exercise of stock options granted to her as a director of Biomea Fusion, Inc.
• No transactions in the Issuer's securities were engaged in by the Reporting Persons during the sixty-day period prior to the filing of this Schedule 13D.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not convey explicit positive or negative sentiment. It updates a significant institutional stake following a capital raise.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the reporting persons regarding the Issuer's future operations or financial performance.

Industry Context

This filing reflects an update to a significant institutional investment in a biotechnology company, Biomea Fusion, Inc., following a public offering. Such disclosures are standard for investors holding more than 5% of a company's shares and provide transparency into major ownership stakes within the healthcare and biotech sectors.

Stakeholder Impact

• Shareholders: Provides transparency on significant institutional and insider ownership, which can influence investor confidence and market perception.
• Company Management: Confirms a substantial stake held by a key institutional investor and a director, potentially aligning interests.

Key Dates

Keywords

Biomea Fusion, Cormorant Asset Management, Bihua Chen, Schedule 13D, Beneficial Ownership, Common Stock, Public Offering, Institutional Investor, Biotechnology, Healthcare